Salarius explores strategic alternatives, cuts workforce >50% after Q2 net loss of $3.9M

Decoy Therapeutics Inc.

FDA removed partial clinical hold on seclidemstat Phase 1/2 Ewing sarcoma trial.
SP-3164 received FDA IND clearance for relapsed/refractory NHL Phase 1 trial.
Cash $11.5M as of June 30, expected to fund operations through Q4 2023.
Net loss Q2 2023 was $3.9M ($1.43/share) vs $4.7M ($2.20/share) in Q2 2022.
Implementing cost-savings plan with >50% workforce reduction to extend resources.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Decoy Therapeutics Inc. reported three and six months ended June 30, 2023 results: net income Net loss for the second quarter of 2023 was $3.9 million, or $1.43 per share, EPS $1.43 per share.

Period: three and six months ended June 30, 2023
Net income: Net loss for the second quarter of 2023 was $3.9 million, or $1.43 per share
EPS: $1.43 per share
Result: reported results

Exact text from the filing

reported financial results for the three and six months ended June 30, 2023

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

Decoy Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001615219-23-000063

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.